Last checked at 
LONDON (Alliance News) - Liquid biopsy firm Angle PLC on Friday said a "leading" customer has set up a multi-centre study using its Parsortix system.
The study is being carried out by the Hellenic Oncology Research Group, at the University of Athens, looking into circulating tumour dna and circulating tumour cells.
The study will involve 50 operable, early stage non-small cell lung cancer patients having liquid biopsy tests prior to surgery, one month after surgery, and then every three to six months until relapse.
Angle said the study should complete by December 2021.
Circulating tumour cells will be harvested from blood using Angle's Parsortix system.
Anglo founder & Chief Executive Andrew Newland commented: "This is another example of Angle's product based leveraged R&D approach delivering key benefits with a major study, which is being developed, executed and funded by a leading customer.
"The high incidence and mortality rates of lung cancer create a pressing need for repeat biopsies to allow personalised medicine and we hope that our Parsortix liquid biopsy system can play a key role in delivering this to the benefit of patients, opening new markets for Angle."
Angle shares were 1.2% lower on Friday at a price of 66.18 pence each.
